icon-    folder.gif   Conference Reports for NATAP  
 
  22nd Conference on Retroviruses and
Opportunistic Infections
Seattle Washington Feb 23 - 26, 2015
Back grey_arrow_rt.gif
 
 
 
BMS-955176: Antiviral Activity and Safety of a Second-Generation HIV-1 Maturation Inhibitor
 
 
  Reported by Jules Levin
CROI 2015 Feb 23-26 Seattle, WA
 
Carey Hwang,1 Dirk Schurmann,2 Christian Sobotha,2 Heather Sevinsky,1 Palanikumar Ravindran,1 Hong Xiao,1 Neelanjana Ray,1 Mark Krystal,3 Ira Dicker3 and Max Lataillade3, on behalf of the BMS HIV Development Team 1 Bristol-Myers Squibb, Research and Development, Princeton, NJ, USA 2 Charite Research Organisation GmbH, Chariteplatz 1, 10117 Berlin, Germany 3 Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA
 
Webcast
http://www.croiwebcasts.org/console/player/25756?mediaType=slideVideo&
 

CROI1.gif

CROI2.gif

CROI3.gif

CROI4.gif

CROI5.gif

CROI6.gif

CROI7.gif

CROI8.gif

CROI9.gif